In vivo assessment of myocardial glucose uptake by positron emission tomography in adults with: The PRKAG2 cardiac syndrome

Circulation: Cardiovascular Imaging

Volumn 2, Issue 6, 2009, Pages 485-491

  Gollob, Michael H ^a   Ha, Andrew C T ^a   Renaud, Jennifer M ^a   DeKemp, Robert A ^a   Thorn, Stephanie ^a   DaSilva, Jean ^a   Garrard, Linda ^a   Yoshinaga, Keiichiro ^a   Abraham, Arun ^a   Green, Martin S ^a   Beanlands, Rob S B ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Cardiomyopathy; Genetics; Positron emission tomography; PRKAG2

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE DERIVATIVE; RUBIDIUM 82; DIAGNOSTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PRKAG2 PROTEIN, HUMAN; RUBIDIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEART LEFT VENTRICLE; HEART MUSCLE; HUMAN; MALE; METABOLIC DISORDER; PATHOPHYSIOLOGY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRKAG2 CARDIAC SYNDROME; PRKAG2 GENE; CASE CONTROL STUDY; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOCARDIOGRAPHY; GENETICS; HEART DISEASE; METABOLISM; MIDDLE AGED; MUTATION; NONPARAMETRIC TEST; PHENOTYPE; SCINTISCANNING; SYNDROME;

ADULT; AMP-ACTIVATED PROTEIN KINASES; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; FEMALE; FLUORODEOXYGLUCOSE F18; HEART DISEASES; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; MUTATION; MYOCARDIUM; PHENOTYPE; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RUBIDIUM RADIOISOTOPES; STATISTICS, NONPARAMETRIC; SYNDROME; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 73449132304     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.109.853291     Document Type: Article

References (29)

1. Dyck JR, Lopaschuk G. AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol. 2006;574:95-112.
2. Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J. 2000;346:659-669.
3. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001;344:1823-1831. (Pubitemid 32538695)
4. Gollob MH, Green MS, Tang AS, Roberts R. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol. 2002;17:229-234.
5. Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, Roberts R. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation. 2001; 104:3030-3033.
6. Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB, Walter M, Li GH, Burgon PG, Maguire CT, Stapleton D, Schmitt JP, Guo XX, Pizard A, Kupershmidt S, Roden DM, Berul CI, Seidman CE, Seidman JG. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation. 2003;107:2850-2856.
7. Murphy RT, Mogensen J, McGarry K, Bahl A, Evans A, Osman E, Syrris P, Gorman G, Farrell M, Holton JL, Hanna MG, Hughes S, Elliott PM, Macrae CA, McKenna WJ. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and WolffParkinson-White syndrome: natural history. J Am Coll Cardiol. 2005;45: 922-930.
8. Gollob MH, Green MS, Veinot JP. Altered AMP-activated protein kinase activity and pathologic cardiac disease. Heart Metab. 2006;32:28-31.
9. Gollob MH. Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. Biochem Soc Trans. 2003;31: 228-231.
10. Sidhu JS, Rajawat YS, Rami TG, Gollob MH, Wang Z, Yuan R, Marian AJ, DeMayo FJ, Weilbacher D, Taffet GE, Davies JK, Carling D, Khoury DS, Roberts R. Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for WolffParkinson-White syndrome. Circulation. 2005;111:21-29.
11. Young LH, Li J, Baron SJ, Russell RR. AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends Cardiovasc Med. 2005; 15:110-118.
12. Gallager BM, Ansari A, Atkins H, Casella V, Christman DR, Fowler JS, Ido T, MacGregor RR, Som P, Wan CN, Wolf AP, Kuhl DE, Reivich M. Radiopharmaceuticals XXVII. 18F-labelled 2-deoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med. 1977;18:990-996.
13. Gropler RJ. PET measurement of myocardial metabolism. In: Di Carli MF, Lipton MJ, editors. Cardiac PET and PET/CT Imaging. New York, NY: Springer; 2007:227-249.
14. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med. 1979;300: 1350-1358.
15. Vitale GD, deKemp RA, Ruddy TD, Williams K, Beanlands RS. Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med. 2001;42: 1730-1736.
16. Beanlands RS, Ruddy TD, deKemp RA, Iwanochko RM, Coates G, Freeman M, Nahmias C, Hendry P, Burns RJ, Lamy A, Mickleborough L, Kostuk W, Fallen E, Nichol G; PARR Investigators. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol. 2002;40: 1735-1743.
17. Parkash R, deKemp RA, Ruddy TD, Kitsikis A, Hart R, Beauchesne L, Williams K, Davies RA, Labinaz M, Beanlands RS. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease. J Nucl Med. 2004;11:440-449.
18. Thompson K, Saab G, Birnie D, Chow BJ, Ukkonen H, Ananthasubramaniam K, Dekemp RA, Garrard L, Ruddy TD, Dasilva JN, Beanlands RS. Is septal glucose metabolism altered in patients with left bundle branch block and ischemic cardiomyopathy? J Nucl Med. 2007;47: 1763-1768.
19. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;273: E214-E223.
20. Patlak C, Blasberg R. Graphical evaluation of blood-brain transfer constants from multiple-time uptake data generalizations. J Cereb Blood Flow Metab. 1985;5:584-590.
21. Maki M, Luotolahti M, Nuutila P, Iida H, Voipio-Pulkki LM, Ruotsalainen U, Haaparanta M, Solin O, Hartiala J, Harkonen R, Knuuti J. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation. 1996;93:1658-1666.
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiographys Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for Chamber Quantification: a report from the American Society of Echocardiographys Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18: 1440-1463.
23. Hudson ER, Pan DA, James J, Lucocq JM, Hawley SA, Green KA, Baba O, Terashima T, Hardie DG. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr Biol. 2003;13:861-866.
24. Polekhina G, Gupta A, Michell BJ, van Denderen B, Murthy S, Feil SC, Jennings IG, Campbell DJ, Witters LA, Parker MW, Kemp BE, Stapleton D. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr Biol. 2003;13:867-871.
25. Sakoda H, Fujishiro M, Fujio J, Shojima N, Ogihara T, Kushiyama A, Fukushima Y, Anai M, Ono H, Kikuchi M, Horike N, Viana AY, Uchijima Y, Kurihara H, Asano T. Glycogen debranching enzyme association with beta-subunit regulates AMP-activated protein kinase activity. Am J Physiol Endocrinol Metab. 2005;289:E474-E481.
26. Polekhina G, Gupta A, van Denderen BJ, Feil SC, Kemp BE, Stapleton D, Parker MW. Structural basis for glycogen recognition by AMP-activated protein kinase. Structure. 2005;13:1453-1462.
27. Banerjee SK, Ramani R, Saba S, Rager J, Tian R, Mathier MA, Ahmad F. A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemia. Biochem Biophys Res Commun. 2007;360:381-387.
28. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans. 2002;30:1064-1070.
29. Nienaber CA, Gambhir SS, Mody FV, Ratib O, Huang SC, Phelps ME, Schelbert HR. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. Circulation. 1993;87:1580-1590.